Laser Focus World is an industry bedrock—first published in 1965 and still going strong. We publish original articles about cutting-edge advances in lasers, optics, photonics, sensors, and quantum technologies, as well as test and measurement, and the shift currently underway to usher in the photonic integrated circuits, optical interconnects, and copackaged electronics and photonics to deliver the speed and efficiency essential for data centers of the future.

Our 80,000 qualified print subscribers—and 130,000 12-month engaged online audience—trust us to dive in and provide original journalism you won’t find elsewhere covering key emerging areas such as laser-driven inertial confinement fusion, lasers in space, integrated photonics, chipscale lasers, LiDAR, metasurfaces, high-energy laser weaponry, photonic crystals, and quantum computing/sensors/communications. We cover the innovations driving these markets.

Laser Focus World is part of Endeavor Business Media, a division of EndeavorB2B.

Laser Focus World Membership

Never miss any articles, videos, podcasts, or webinars by signing up for membership access to Laser Focus World online. You can manage your preferences all in one place—and provide our editorial team with your valued feedback.

Magazine Subscription

Can you subscribe to receive our print issue for free? Yes, you sure can!

Newsletter Subscription

Laser Focus World newsletter subscription is free to qualified professionals:

The Daily Beam

Showcases the newest content from Laser Focus World, including photonics- and optics-based applications, components, research, and trends. (Daily)

Product Watch

The latest in products within the photonics industry. (9x per year)

Bio & Life Sciences Product Watch

The latest in products within the biophotonics industry. (4x per year)

Laser Processing Product Watch

The latest in products within the laser processing industry. (3x per year)

Get Published!

If you’d like to write an article for us, reach out with a short pitch to Sally Cole Johnson: [email protected]. We love to hear from you.

Photonics Hot List

Laser Focus World produces a video newscast that gives a peek into what’s happening in the world of photonics.

Following the Photons: A Photonics Podcast

Following the Photons: A Photonics Podcast dives deep into the fascinating world of photonics. Our weekly episodes feature interviews and discussions with industry and research experts, providing valuable perspectives on the issues, technologies, and trends shaping the photonics community.

Editorial Advisory Board

  • Professor Andrea M. Armani, University of Southern California
  • Ruti Ben-Shlomi, Ph.D., LightSolver
  • James Butler, Ph.D., Hamamatsu
  • Natalie Fardian-Melamed, Ph.D., Columbia University
  • Justin Sigley, Ph.D., AmeriCOM
  • Professor Birgit Stiller, Max Planck Institute for the Science of Light, and Leibniz University of Hannover
  • Professor Stephen Sweeney, University of Glasgow
  • Mohan Wang, Ph.D., University of Oxford
  • Professor Xuchen Wang, Harbin Engineering University
  • Professor Stefan Witte, Delft University of Technology

Windtree Therapeutics (NASDAQ: WINT) Granted EU Patent for SERCA2a Activator Therapy for Heart Failure

Windtree Therapeutics, Inc. (NASDAQ: WINT) is engaged as a biotechnology company, which is focused on late-stage treatments for cardiovascular disorders. Shares of the cardiovascular biotech company are skyrocketing 213%, through afternoon trading on Monday, April 17, 2023. Over the past three months, Windtree Therapeutics has seen an average daily volume of 147,720 shares. However, a volume of 4.15 million shares, or a dollar volume of around $62.08 million, has already exchanged hands through afternoon trading.

Shares of Windtree Therapeutics are surging after the company announced it has been granted Patent No. 3599243 by the European Patent Office. This patent, titled: “17BETA-HETEROCYCLYL-DIGITALIS LIKE COMPOUNDS FOR THE TREATMENT OF HEART FAILURE,” grants protection until July 2038. The patent covers the revolutionary SERCA2a Activator class of drugs, which have dual mechanisms of action – they inhibit the Na+/K+ pump and activate SERCA2a, in addition to offering pure SERCA2a activators.

The SERCA2a enzyme, which is decreased in heart failure, has presented an opportunity for potential therapeutic advancement. Windtree’s strategy of dual-mechanism compounds, with istaroxime as its lead candidate for heart failure and cardiogenic shock treatment, is aiming to take advantage of this exciting chance.

Dual mechanism compounds are developed to provide both oral and intravenous therapies for heart failure treatment, whether it be an inpatient hospital stay for an acute case or an outpatient oral treatment for a chronic one.

Windtree Therapeutics is forging a multi-asset empire, centered around compounds with the capability to trigger SERCA2a. As part of its heart failure platform, they are also actively pursuing follow-up oral pre-clinical SERCA2a activator assets. Beyond istaroxime, Windtree boasts rostafuroxin, a novel, specifically designed medication targeting hypertensive patients with certain genetic profiles.

Disclosure: No position. Spotlight Growth has no relationships with any of the companies mentioned in this article and did not receive payment in any form for its creation. This is an opinion article and is not meant to be financial advise. We are not broker-dealers or investment professionals. Please conduct your own due diligence. For more information on our disclosures, please visit: https://spotlightgrowth.com/disclosures/

The post Windtree Therapeutics (NASDAQ: WINT) Granted EU Patent for SERCA2a Activator Therapy for Heart Failure appeared first on Spotlight Growth.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.